Drug intelligence / Profile preview

icopezil

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Icopezil is a **small molecule acetylcholinesterase inhibitor** developed by **Pfizer** for the treatment of cognitive impairment associated with **Alzheimer's disease** and related dementias. It is a **benzoxazol derivative** designed to selectively inhibit **acetylcholinesterase** with high selectivity over butyrylcholinesterase, thereby increasing synaptic acetylcholine levels and aiming to improve cognitive symptoms. The program advanced into **Phase II clinical development** in Japan and the United States, but development was later **discontinued**.

Other names: icopezilicopezil maleate

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on icopezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on icopezil.

Explore the full profile